Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
Sangamo Therapeutics预计，2024年的总运营支出约为1.45亿至1.65亿美元
Financial Guidance for 2024
2024年的财务指导
On a GAAP basis, we expect total operating expenses in the range of approximately $145 million to $165 million in 2024, which includes non-cash stock-based compensation expense and depreciation and amortization, subject to additional funding.
按公认会计原则计算，我们预计2024年的总运营支出约为1.45亿美元至1.65亿美元，其中包括非现金股票薪酬支出以及折旧和摊销，但须视额外资金而定。
We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, and depreciation and amortization of approximately $7 million, in the range of approximately $125 million to $145 million in 2024, subject to additional funding.
我们预计，非公认会计准则的总运营支出，不包括估计的约1300万美元的非现金股票薪酬支出，以及约700万美元的折旧和摊销，在2024年约1.25亿美元至1.45亿美元之间，视额外资金而定。